Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease
NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease
NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich’s ataxia
Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Capsida for CAP-002.
Latigo Biotherapeutics, Inc. (“Latigo”) today announced that the first participant has been dosed in its Phase 1 clinical trial of LTG-305, a potential best-in-class non-opioid therapeutic candidate for the treatment of chronic pain.
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease (TED)
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients
Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
